SEATTLE — In eyes with center-involved diabetic macular edema, using bevacizumab first and switching to aflibercept if needed is more cost-effective over 2 years as compared with aflibercept monotherapy, according to DRCR Protocol AC.
Protocol T showed benefit of aflibercept over bevacizumab at 1 and 2 years, but the 15-letter gain at 2 years was comparable between the two drugs. Given the cost difference of these findings, Protocol AC investigated the potential cost-effectiveness of using bevacizumab first with a switch to aflibercept if needed in eyes with moderate to severe (Read more...)